-
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Tuesday, October 14, 2025 - 1:08pm | 614Read More...Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing exceptional strength. View the charts here. The hedge fund holds a 7.2% stake and is the company's...
